Key result
A hypercoagulable state was identified in 32% of patients with upper-extremity deep venous thrombosis, with antiphospholipid antibodies being the most frequent abnormality (27%).
Why the study?
What is the prevalence of hypercoagulable states in patients with upper-extremity deep venous thrombosis?
Population
Consecutive patients with upper-extremity deep venous thrombosis (DVTUE)
Design
Cohort
Authors
Loading...
Supports consideration of antiphospholipid antibody testing in upper-extremity DVT; leaves open whether identifying hypercoagulability changes outcomes.
Observational
What is the prevalence of hypercoagulable states in patients with upper-extremity deep venous thrombosis?
Antiphospholipid antibodies are frequently found in patients with upper-extremity DVT, whereas common genetic thrombophilias like Factor V Leiden do not appear to play a major pathogenetic role.
Leebeek et al. (2001) conducted an observational in Upper-extremity deep venous thrombosis (DVTUE). Hypercoagulable state was evaluated on Presence of a hypercoagulable state. A hypercoagulable state was identified in 32% of patients with upper-extremity deep venous thrombosis, with antiphospholipid antibodies being the most frequent abnormality (27%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: